News | March 14, 2026
APL Healthcare’s Unit-IV classified as VAI by the USFDA
This inspection is now closed
This inspection is now closed
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
The company has been issued ‘Form 483’ with two observations
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
